Seres Therapeutics (MCRB) Tops Q3 EPS by 4c

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.46), $0.04 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $13.02 million versus the consensus estimate of $10.38 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c